386 related articles for article (PubMed ID: 15675088)
1. The burgeoning science of genetics and the impact on public policy.
Hatch OG
J Biolaw Bus; 2004; 7(4):3-6. PubMed ID: 15675088
[TBL] [Abstract][Full Text] [Related]
2. Compulsory licensure: the case of Cipro and beyond.
Chakrabarty AM
Am J Bioeth; 2002; 2(3):40. PubMed ID: 12230853
[No Abstract] [Full Text] [Related]
3. Who are the guardians guarding?
Trachtman H
Am J Bioeth; 2002; 2(3):46-8. PubMed ID: 12230858
[No Abstract] [Full Text] [Related]
4. The Cipro patent and bioterrorism.
Kaye KS; Kaye D
Am J Bioeth; 2002; 2(3):41-2. PubMed ID: 12230854
[No Abstract] [Full Text] [Related]
5. The attack of the clones: patent law and stem cell research.
Rimmer M
J Law Med; 2003 May; 10(4):488-505. PubMed ID: 12852321
[TBL] [Abstract][Full Text] [Related]
6. The Human Genome Project in the United States: a perspective on the commercial, ethical, legislative and health care issues.
Mackler BF; Barach M
J Int Bioethique; 1991; 2(3):149-57. PubMed ID: 11654898
[TBL] [Abstract][Full Text] [Related]
7. It is not unethical, though it is often unwise, to override patents.
Leventer H
Am J Bioeth; 2002; 2(3):50-1. PubMed ID: 12230860
[No Abstract] [Full Text] [Related]
8. US policy may encourage counterfeit drugs.
Bouchie A
Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826
[No Abstract] [Full Text] [Related]
9. Supporting the work of lesser geniuses: an argument for removing obstructions to human embryonic stem cell research.
Hazuka CD
Univ Miami Law Rev; 2002 Oct; 57(1):157-220. PubMed ID: 15156896
[No Abstract] [Full Text] [Related]
10. Regulation of biotechnology by executive orders: questions about constitutionality, legality and overall fairness to the American public.
Cuomo P
J Biolaw Bus; 2005; 8(2):30-42. PubMed ID: 16538813
[TBL] [Abstract][Full Text] [Related]
11. Patent prosecution strategies for stem cell related applications.
Kumar R; Yeh JJ; Fernandez D; Hansen N
J Biomol Screen; 2007 Sep; 12(6):769-74. PubMed ID: 17848639
[TBL] [Abstract][Full Text] [Related]
12. Patents: the public interest versus the private privilege.
Parsi KP; Egan EA
Am J Bioeth; 2002; 2(3):45-6. PubMed ID: 12230857
[No Abstract] [Full Text] [Related]
13. The policy outlook from the Hill.
Vastag B
Nat Biotechnol; 2007 Jan; 25(1):13-6. PubMed ID: 17211381
[No Abstract] [Full Text] [Related]
14. Patents on parts of the human body: salient issues under EC and WTO law.
Herdegen M
J World Intellect Prop; 2002 Mar; 5(2):145-55. PubMed ID: 15986546
[No Abstract] [Full Text] [Related]
15. Not taking, just borrowing: government use of patented drugs.
Ossorio PN
Am J Bioeth; 2002; 2(3):51-2. PubMed ID: 12230861
[No Abstract] [Full Text] [Related]
16. Patent crunch pending.
Wadman M
Nature; 2007 Oct; 449(7163):651. PubMed ID: 17968400
[No Abstract] [Full Text] [Related]
17. Beyond government intervention: drug companies and bioethics.
Dresser R
Am J Bioeth; 2002; 2(3):42-3. PubMed ID: 12230855
[No Abstract] [Full Text] [Related]
18. The allure and peril of genetics exceptionalism: do we need special genetics legislation?
Suter SM
Wash Univ Law Q; 2001; 79(3):669-748. PubMed ID: 12741377
[No Abstract] [Full Text] [Related]
19. Patent law and human genome research at the crossroads: the need for Congressional action.
McKay DL
Santa Clara Comput High Technol Law J; 1994; 10(2):465-98. PubMed ID: 16514752
[No Abstract] [Full Text] [Related]
20. Agbiotech issues climb US political agenda.
Fox JL
Nat Biotechnol; 2002 Dec; 20(12):1179-80. PubMed ID: 12454658
[No Abstract] [Full Text] [Related]
[Next] [New Search]
